Rein Therapeutics Inc. (RNTX) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $1.63. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is RNTX = $6 (+268.1% upside).
Valuation: RNTX trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Net income is $50M (loss), growing at -133183.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $0 against $17M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.7 (tight liquidity). Debt-to-assets is 0%. Total assets: $24M.
Analyst outlook: 0 / 1 analysts rate RNTX as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).
